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Neem leaf glycoproteina b s t r a c t
Therapy with neem leaf glycoprotein (NLGP) inhibits murine B16-melanoma in vivo and improves surviv-
ability. Studies on tumor-microenvironment (TME) from NLGP treated mice (NLGP-TME) suggests that
anti-tumor effect is directly associated with enhanced CD8+T cell activity, dominance of type 1 cyto-
kines/chemokine network with downregulation of suppressive cellular functions. NLGP-TME educated
CD8+T cells showed higher perforin and granzymeB expression with greater in vitro cytotoxicity against
B16 melanoma. These CD8+T cells showed proportionally lower FasR expression, denotes prevention
from activation induced cell death by NLGP. Accumulated evidences strongly suggest NLGP inﬂuenced
normalized TME allows CD8+T cells to perform optimally to inhibit melanoma growth.
 2013 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Melanomas are considerably more immunogenic than other tu-
mors [1], but current immunotherapeutic approaches for mela-
noma patients have gained limited success [2]. Recent study
identiﬁed tumor promoting effect of suppressor cells within mela-
noma tumor microenvironment (TME) [3]. Although, melanoma-
speciﬁc CD8+T-cell responses can often be generated in patients
naturally or through vaccination [4], tumor grows consistently
and suggests dampening of tumor-speciﬁc immune responses.
Regulatory immune cells and suppressive cytokine milieu within
TME negatively instruct effector T-cell functions. Accordingly,
TME organized immunosuppressive network protects tumor cells
from being attacked by immune effector cells [5] leading to tumor
growth, metastasis and failure of immunotherapeutic modalities
[6]. Thus, effector T-cell activation needs to be assisted by the nor-
malization of TME.
Neem leaf preparation (NLP) is tested extensively in prophylac-
tic settings on murine carcinoma, melanoma and sarcoma [7,8].
Neem leaf glycoprotein (NLGP), a nontoxic immunomodulatory
principle of NLP, was examined in vitro [9] and in peripheral im-mune systems of tumor bearers [10–12], it activates effector cells,
including T [9,13] and NK-cells [13], matures dysregulated den-
dritic cells [9], downregulates suppressor cells [14], polarizes type2
immune pattern into type1 by altering cytokine-chemokine signal-
ing [15,16]. In this perspective, here, we wanted to examine the
therapeutic role of NLGP on mouse melanoma and to understand
the mechanism of alteration in tumor growth by analyzing TME.
NLGP altered melanoma TME was specially tested for any notewor-
thy modulation in the functioning of CD8+ cytotoxic T-cells that
could be translated into maximum therapeutic beneﬁts.Materials and methods
Reagents and antibodies
Duelbeco’s Modiﬁed Eagle’s medium (DMEM) and fetal bovine
serum (FBS) were purchased from Life Technologies (NY, USA).
Magnetic Activated Cell Sorter (MACS) was procured fromMiltenyi
Biotech (GmbH, Germany). CD4-FITC/Cy-chrome, GR1-FITC mAbs
were procured from BD Pharmingen (San Diego, CA, USA). CD25
(PE), CD69 (FITC) were purchased from Biolegend (USA) and
cytokine neutralizing mAbs were obtained from e-Biosciences.
Fluorescence- or peroxidase-labeled secondary antibodies
were procured from e-Biosciences. CytoFix/CytoPerm solutions,
IFNc/IL-10 estimation kits, 3,30,5,50-tetramethylbenzidine sub-
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icity detection LDH release kit was procured from Roche Diagnos-
tics (Mannham, Germany). Chemiluminescence detection kit was
purchased from Pierce (Rockford, IL, USA). Tri-reagent for RNA iso-
lation and RevertAid™ First Strand cDNA Synthesis Kit were pro-
cured from Invitrogen, Camarillo, CA, USA and Fermentas, K1622,
USA, respectively. Reverse transcription-PCR primers were de-
signed and procured from MWG-Biotech AG (Bangalore, India).Neem leaf glycoprotein (NLGP)
Extract from neem (Azadirachta indica) leaves was prepared by
the method as described [8,7]. Mature leaves of same size and color
(indicative of same age), taken from a standard source were shed-
dried and pulverized. Leaf powder was soaked overnight in phos-
phate buffered saline (PBS); pH 7.4, supernatant was collected by
centrifugation at 1500 rpm. Neem leaf preparation (NLP) was then
extensively dialyzed against PBS, pH 7.4 and concentrated by
Centricon Membrane Filter (Millipore Corporation, Bedford, MA,
USA) with 10 kDa molecular weight cut off. Glycoprotein present
in this preparation (NLGP) was isolated and characterized by the
method described [8,16]. NLGP is a puriﬁed glycoprotein which
gives single band in native page, three different bands in SDS–PAGE
having molecular weight of 47, 23 and 15 kDa. Its molecular
weight is around 90 kDa. The purity of NLGP was checked by Size
Exclusion-HPLC (SE-HPLC) in a protein PAK 300 SW column of
7.5 mm (ID)  30 cm, as described [9]. Quantiﬁcation NLGP is done
by measuring its protein concentration [19].Table 1
Primer sequences of various cytokine genes studied.
Name Primer sequences (50-30) Product size
b-Actin-forward CAACCGTGAAAAGATGACCC 228 bp
b-Actin-reverse ATGAGGTAGTCTGTCAGGTC
IFNg-forward ACTGGCAAAAGGATGGTGAC 237 bp
IFNg-reverse TGAGCTCATTGAATGCTTGGAnimals, tumor cells and NLGP treatment
Female C57BL6/J mice, 4–6 weeks of age with average body
weight of 25 g were obtained from Institutional Animal Facilities,
CNCI, Kolkata, India. Autoclaved dry pellet diet (Epic Laboratory
Animal Feed, Kalyani, India) and water were given ad libitum. Ani-
mal experiments were performed according to the guidelines
established by the Institutional Animal Care and Ethics Committee
of CNCI, Kolkata, India and this committee approved the present
study. Solid melanoma tumors were developed in mice by inocula-
tion of 2  105 B16 Melanoma F10 cells (maintained in DMEM)
subcutaneously into syngenic mice and allowed to grow as solid
tumor. Tumors were removed from diseased mice and used in un-
der mentioned experiments.
NLGP was administered subcutaneously in the left ﬂange to fe-
male C57BL6/J mice at 25 lg/mice dose weekly for 4 weeks in total
in the experimental group.IL-2-forward GCAGGCCACAGAATTGAAAG 207 bp
IL-2-reverse TCCACCACAGTTGCTGACTC
IL-12-forward CCTGCATCTAGAGGCTGTCC 243 bp
IL-12-reverse CATCTTCTTCAGGCGTGTCA
IL-6-forward TTCCATCCAGTTGCCTTCTT 199 bp
IL-6-reverse CAGAATTGCCATTGCACAAC
IL-10-forward CCAAGCCTTATCGGAAATGA 162 bp
IL-10-reverse TTTTCACAGGGGAGAAAATCG
TGF-b-forward TGCGCTTGCAGAGATTAAAA 197 bp
TGF-b-reverse GCTGAATCGAAAGCCCTGTA
VEGFR2-forward ACAGACAGTGGGATGGTCC 271 bp
VEGFR2-reverse AAACAGGAGGTGAGCGCAG
VEGFR1-forward CCAACTACCTCAAGAGCAAAC 315 bp
VEGFR1-reverse CCAGGTCCCGATGAATGCAC
Arg1-forward AAGAAAAGGCCGATTCACCT 201 bp
Arg1-reverse CACCTCCTCTGCTGTCTTCC
Perforin-forward GATGTGAACCCTAGGCCAGA 161 bp
Perforin-reverse GGTTTTTGTACCAGGCGAAA
Granzyme B-forward TCGACCCTACATGGCCTTAC 198 bp
Granzyme B-reverse TGGGGAATGCATTTTACCATTumor microenvironment
Tumor tissues were harvested from experimental animals and
weighed. The identical weight of tumor tissues from NLGP and
PBS mice was minced and exposed to repetitive freeze-thaw cycles
as described [17,18]. Prepared lysates were centrifuged at
10,000 rpm for 10 mins and supernatant was collected to use as
TME. TME from either PBS or NLGP treated mice was designated
as PBS-TME and NLGP-TME respectively. These TMEs were used
for in vitro treatment and estimation of soluble cytokines and
growth factors. For western blot analysis after repetitive freeze-
thaw cycles tumors were dissolved in RIPA buffer and kept at
4C for 30 mins and supernatants were collected by centrifugation.
Protein concentration was measured by Lowry’s method using
Folin-phenol reagent [19].Cytokine detection assay
To quantify cytokines, solid tumors harvested at different days
after tumor inoculation and TME was prepared as mentioned
above. Secretion of different cytokines (IFNc, IL-12p70, IL-10,
IL-6, IL-2 and TGFb) within TME was assessed by ELISA and optical
density was measured at 450 nm using microplate reader (BioTek
Instruments Inc., Vermont, USA).
TME educated effector cells
Splenic mononuclear cells (1X106 cells) from normal mice, were
puriﬁed by density gradient centrifugation on Lymphocyte sepa-
rating solution (LSM) and exposed to either PBS-TME or NLGP-
TME (10 lg of protein) for 120 hrs at 37 C on anti-CD3 antibody
coated plate with supply of 5% CO2. After incubation, non-adherent
fractions were collected as effector cells. CD8+T-cells were puriﬁed
from effector cell population using magnetic assisted cell sorting
(MACS).
Puriﬁcation of CD8+T-cells, regulatory T cells (Tregs) and myeloid
derived suppressor cells (MDSCs) from solid melanoma by MACS
CD8+, CD4+CD25+ and GR1+ cells were puriﬁed by MACS. In
brief, after harvesting tumor from tumor-bearing mice, tumor tis-
sues were minced and treated with collagenase (1 mg/ml) and
hyanuronidase (1 mg/ml) for 10 mins. Digested tissues then passed
through a cell strainer (BD BioSciences, USA) to get single cells. Sin-
gle cells were labeled with cocktail of antibodies, conjugated with
magnetic beads and passed through a magnetic column. Purity of
cells was checked by ﬂow cytometry by labeling with appropriate
antibodies.
Functional assays for T cells
RBC depleted splenic mononuclear cells (1  106 cells) were
incubated with either PBS-TME or NLGP-TME for 120 hrs at 37 C
with supply of 5% CO2. Following co-incubation non-adherent frac-
tions were collected as effector cells and CD8+T-cells were puriﬁed
from this cellular population by MACS. TME exposed CD8+T cells
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natants were analyzed for extracellular release of IFNc by ELISA
(using kit, OptEIA™, BD Pharmingen) following the manufacturer’s
protocol. (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) colorimetric assay was used to assess T-cell prolif-
eration after exposure to TME [9].Isolation of RNA and RT-PCR analysis
Total RNA was isolated from solid tumors (single-cell suspen-
sions were obtained by enzymatic digestion) or puriﬁed cell popu-
lations from solid tumors. RNA was prepared using the Tri-reagentTable 2
Primer sequences of various chemokine genes studied.
Name Primer sequences (50-30) Product size
CXCR3-forward GCTGCTGTCCAGTGGGTTTT 67 bp
CXCR3-reverse AGTTGATGTTGAACAAGGCGC
CXCL9-forward TGGGCATCATCTTCCTGGAG 204 bp
CXCL9-reverse CCGGATCTAGGCAGGTTTGA
CXCL10-forward CCAAGTGCTGCCGTCATTTT 177 bp
CXCL10-reverse CTCAACACGTGGGCAGGATA
CCR5-forward ACTGCTGCCTAAACCCTGTCA 78 bp
CCR5-reverse GTTTTCGGAAGAACACTGAGAGATAA
CCL3-forward CCTCTGTCACCTGCTCAACA 163 bp
CCL3-reverse GATGAATTGGCGTGGAATCT
CCL4-forward GCTGTGGTATTCCTGACCAAA 196 bp
CCL4-reverse AAATCTGAACGTGAGGAGCAA
CCL5-forward CCCTCACCATCATCCTCACT 186 bp
CCL5-reverse TCCTTCGAGTGACAAACACG
CCL8-forward ACGCTAGCCTTCACTCCAA 231 bp
CCL8-reverse TCTGGAAAACCACAGCTTCC
CXCR4-forward TCAGTGGCTGACCTCCTCTT 203 bp
CXCR4-reverse CTTGGCCTCTGACTGTTGGT
CXCL12-forward CTGCATCAGTGACGGTAAACC 142 bp
CXCL12-reverse CAGCCGTGCAACAATCTGAAG
Fig. 1. C57BL6/J mice were inoculated with B16 melanoma F10 cells (2  105 cells/mice).
with NLGP (25 lg) s.c. once a week for 4 weeks in total and mice of control group (n = 12
day 36 after the initiation of therapy (A) and their mean survival (B) are presented.
representative mice of each group at three different days (day 10, 15 and 20) are shown
presented.and cDNA synthesis was carried out using cDNA Synthesis Kit fol-
lowing the manufacturer’s protocol and PCR were carried out using
gene-speciﬁc primers. The oligonucleotide primers used are listed
in Table 1 and Table 2. PCR products were identiﬁed by image anal-
ysis software for gel documentation (Gel Doc™ XR+ system, Bio-
Rad, USA) following electrophoresis on 2% agarose gels stained
with ethidium bromide.
Western blot analysis
The tumor tissue lysate or cellular lysate (50 lg) were separated
on 6–20% SDS–polyacrylamide gel and transferred onto a polyvi-
nylidene ﬂuoride (PVDF) membrane (Millipore, USA) using the Bio-
Rad Gel Transfer system. Immunoreactive proteins were detected
by addition of the HRP color development reagent according to
manufacturer’s protocol.
Flow cytometric analysis of immune cellular markers
Flow cytometric analysis for surface phenotypic markers for
T-cells, MDSCs and Tregs was performed after labeling with differ-
ent anti-mouse ﬂuorescence labeled antibodies (1 ll antibody for
1  106 cells) (CD8, CD4, CD25, CD11b, perforin, granzyme B,
CD69, Gr1 and FasR) for 30 min as per manufacturer’s recommen-
dation. Cytometry was performed by FACS Caliber ﬂow cytometer
(Becton Dickinson, Mountainview, CA) and data was analyzed by
Cell Quest (Becton Dickinson, Mountainview, CA) and FlowJo (Tree
Star Inc., Ashland, USA) software. Percentage of each positive pop-
ulation and mean ﬂuorescence intensity (MFI) were determined by
using region statistics.
In vitro cytotoxicity with TME educated CD8+T-cells
Cytotoxicity of T-cells (primed with TME) against mouse B16
melanoma cells was tested by lactate dehydrogenase (LDH) releaseAfter formation of palpable tumor, mice of experimental group (n = 12) was treated
) received PBS only. Tumor (in mm3) growth of mice of each group is presented till
Arrows indicate the time points of NLGP injections. Photographs of tumors from
. Percent of tumor reduction in NLGP treated mice in comparison to PBS controls is
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noma cells were plated as target in 96-well cell culture plates. TME
exposed CD8+T-cells were added in triplicate as effector cells
(Effector:Target; 10:1) in each well and incubated overnight.
Cell-free supernatants were used to measure the level of released
LDH using the formula:
%Cytotoxicity ¼ ðLysis from Effectorþ Target Mixture
 Lysis from Effector onlyÞ
 Spontaneous Lysis=Maximum Lysis
 Spontaneous Lysis 100:Statistical analysis
All results represent the average of ﬁve separate in vitro and
three in vivo experiments. The number of experiments is men-
tioned in the results section and legends to ﬁgures. In each exper-
iment, a value represents the mean of three individual
observations and is presented as mean ± standard deviation (SD).Fig. 2. Single cell suspension was prepared from tumors (day 20) of PBS and NLGP treate
cells with CD69, perforin, granzymeB antibodies and analyzed by ﬂow cytometry after
proﬁling of various genes was studied by RT-PCR. (C) Cells were stained together with Fa
measured by ﬂow cytometry. (D) Cells were stained with CD11b and Gr1 antibodies and
were performed using Flowjo software, p < 0.05, p < 0.001. (E) Gr1+ cells were puriﬁed
PCR. (F) Cell suspensions were labeled together with CD4 and CD25 and percentage of CD
(G) CD4+CD25+ cells were puriﬁed from tumors by MACS and expressions of Foxp3, VEGStatistical signiﬁcance was established by unpaired t-test using
INSTAT 3 Software.Results
NLGP therapy restricts B16 melanoma growth in C57BL/6 mice
Mice with established B16melanoma growth on around 7th day
of tumor inoculation were either PBS treated or administered with
NLGP (25 lg/mice) weekly for 4 weeks in total. Result of such treat-
ment schedule onmelanoma bearingmice is presented in Fig. 1A–C,
and indicates signiﬁcant protection. This result shows progression
of the disease in 13/20 (65%) NLGP treated mice, in comparison to
19/20 (95%) mice in control group. Moreover, tumor volume in
NLGP treated mice with progressive disease is signiﬁcantly less
than controls (Fig. 1a, b). Again, number of tumor free animals is
more in the mice group that received NLGP (7/20 (35%)) than in
the group that received PBS only (1/20 (5%)) by 60 days post-tumor
inoculation. Survival beneﬁt of NLGP treatedmice is 95% (19/20) on
day 60 vs 5% (1/20) in PBS group (p < 0.001) (Fig. 1c).d mice. (A) Proportion of activated T cells were measured by double labeling of CD8+
gating CD8+T cells. (B) CD8+T cells were puriﬁed from tumors and transcriptional
sR and CD8 antibodies and percent of FasR+ cells within CD8+T cell population were
percentage of Gr1+ cells were measured within CD11b+ population, all FACS analysis
from tumors by MACS and expressions of Arg1, IL-10 and TGF-bwere studied by RT-
25+ cells was shown within CD4+ T cell population, as assessed by ﬂow cytometry.
FR1 and VEGFR2 were studied by RT-PCR.
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As we reported previously that NLGP can’t kill tumor cells di-
rectly [14] and modulates immune system [15,20], next we at-
tempted to understand the immune mechanism of NLGPFig. 3. NLGP modulates immunosuppressive cytokine milieu within TME. (A) Tumor tissu
freeze-thaw technique in PBS supplemented with a cocktail of protease inhibitors. Tumor
case) were assessed for IL-10, IL-6, TGFb, IFNc, IL-12, and IL-2 by ELISA in three differe
Np = 0.005, p = 0.001, jp = 0.03, in comparison to PBS treated. (B) Total RNA was isolate
IFNc, IL-2, IL-12, IL-6 and IL-10 by RT-PCR. (C) IL-6, TGFb, IL-12, STAT3 and pSTAT3 leve
(n = 4, in each case) by Western blot analysis. Bar diagrams indicates quantitative expremediated restriction of B16 melanoma growth by studying effector
and regulatory immune cells within TME. A considerable activation
of CD8+T cells was observed within NLGP-TME in comparison to
PBS-TME, as represented by higher expression of CD69. These cells
also expressed a greater proportion of IFNc, perforin andes (100 mg) were harvested from B16Melanoma bearing C57BL6/J mice and lysed by
tissue lysates, representing TME from either PBS or NLGP treated mice (n = 6 in each
nt time points and quantitated as pg/mg of tumor tissues ± SE. p = 0.01, p = 0.02,
d from tumors of PBS and NLGP treated mice (n = 4, in each case) to analyze genes of
ls were studied in total protein isolated from tumors of PBS and NLGP treated mice
ssions depicted in the RT-PCR and western blot analysis.
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ated by ﬂow cytometry and RT-PCR (Fig. 2A and B). We also found
a much reduced FasR positivity within CD8+T cells within NLGP-
TME. This ﬁnding indicates that NLGP might protect CD8+T cells
from activation induced cell death (AICD) and helps their better
survival within TME (Fig. 2C).
At the same time, a much lower proportion of MDSCs were
found in tumors from NLGP treated mice (Fig. 2D), however, no sig-
niﬁcant change was detected in case of regulatory T-cells (Fig. 2E).
mRNAs were isolated from Puriﬁed MDSCs and Tregs from both
PBS and NLGP TME were used to isolate mRNAs and subjected to
transcriptional analysis for some functionally relevant genes for
MDSCs and Tregs. In puriﬁed MDSCs from NLGP-TME, Arginase1,
TGFb and IL-10 were signiﬁcantly downregulated (Fig. 2E). Inspite
of decrease in number of Tregs in NLGP treated group, a prominent
down-regulation of Foxp3 and VEGFR2 gene expression was noted
without any change in VEGFR1 (Fig. 2F).NLGP optimizes the level of type1 and regulatory cytokines within TME
Optimization of the cellular functions within TME of NLGP trea-
ted mice prompted us to evaluate the status of secretory cytokines
and growth factors. Cellular stress, aberrant growth and death of
cancer cells generate many tumor associated factors that canFig. 4. NLGP normalizes chemokine network within TME and NLGP normalizes T cell fu
mice. cDNA was prepared from RNA and RT-PCR was performed for different chemokine r
Bar diagrams indicates quantitative expressions depicted in the RT-PCR analysis. NLGP n
tumors of different days, obtained from PBS and NLGP treated mice (PBS-TME and NLGP
TME for 120 hrs. (D) MNCs were then allowed to proliferate for 72 hrs and proliferation
MNCs (by MACS) were further cultured for 48 hrs. Cell supernatants were used to measu
cultured with B16 melanoma cells to determine the tumor cell cytotoxicity by LDH releas
T cells vs same exposed to NLGP-TME on day 15 and day 20.enhance type2 inﬂammatory responses that lead to tumor progres-
sion [21]. To elucidate cytokine and growth factor status within
TME, tumor lysates from NLGP and PBS treated groups were ana-
lyzed at three different time points (after tumor inoculation) by
ELISA and immunoblotting. Tumors of NLGP treated mice exhibited
signiﬁcant up-regulated level of IFNc, IL-2 and IL-12 (Fig. 3B–C) in
day dependent manner and reduced release of IL-6, IL-10 and TGFb
(Fig. 3A,C) within TME, in comparison to PBS treated controls. In
accordance with our earlier observation on NLGP mediated
down-regulation of phosphorylation of STAT3 [14], here, we ob-
served day dependent down-regulation of the same within
NLGP-TME (Fig. 3C).NLGP potentiates the migration of CXCR3+ leukocytes against
chemokine gradients within TME
Expression status of chemokine receptors/ligands is extremely
important for T-cell migration within TME [22]. Using RT-PCR we
have studied the status of chemokine receptors (ccr5, cxcr3 and
cxcr4) and ligands (ccl3, ccl4, ccl5, ccl8, cxcl9, cxcl10 and cxcl12)
at transcriptional level within TME. Results suggested upregulation
of chemokine receptors, cxcr3 and ccr5, in NLGP-TME (Fig. 4). Li-
gands for cxcr3 (cxcl9, cxcl10) and ccr5 (ccl3, ccl4, ccl5 and ccl8)
were also upregulated within NLGP-TME to varied extent (Fig. 4Anctions within TME. Total RNA was isolated from tumors of PBS and NLGP treated
elated genes, (A) ccr5, ccl3, ccl4, ccl5, ccl8; (B) cxcr3, cxcl9, cxcl10; (C) cxcr4, cxcl12.
ormalizes T cell functions within TME. Lysates were prepared from B16 melanoma
-TME). MNCs from normal C57BL6/J mice were incubated with PBS-TME and NLGP-
was determined by MTT assay. p = 0.01. (E) CD8+T cells puriﬁed from TME exposed
re IFNc level by ELISA. p = 0.001. (F) Puriﬁed CD8+T cells, as mentioned in E, were
e assay. p < 0.001. In every case, comparison was made between PBS-TME exposed
e86 S. Barik et al. / Trials in Vaccinology 4 (2015) e80–e87and B). Downregulated expression of cxcr4 and cxcl12 in case of
NLGP-TME than PBS controls indicated diminished regulatory cell
(particularly MDSC) recruitment (Fig. 4C) at tumor site.NLGP-TME educated CD8+T-cells exhibit effector functions against
melanoma cells
To further corroborate our in vivo results that normalization of
TME by NLGP is directly associated with functional activation of
CD8+T-cells, we exposed mononuclear cells from naive mice for
120 hrs to TME (prepared from tumors of NLGP and PBS treated
mice) and CD8+T-cells were puriﬁed by MACS and analyzed subse-
quently. Functional analysis of such T-cells revealed that exposure
of NLGP-TME helped them to proliferate more, release IFNc in sub-
stantial quantity and lysed melanoma cells more conspicuously
compared to PBS controls (Fig. 4D–F).Discussion
Conventional therapies can reduce the tumor mass either by
surgery, chemotherapy or by radiation mediated tumor killing
[23,24]. Unfortunately, none is efﬁcient for complete removal of tu-
mor cells [25]. At the same time, these therapies promote immuno-
suppressive milieu by expansion of suppressor cells, paralysis of
immune effector cells and creation of protumor cytokine-
chemokine milieu within TME [26]). Such condition in TME further
expands the residual tumor mass that often result in recurrence of
the disease [27], by inducing active immune tolerance and
escaping immune surveillance, thus fostering easy tumor cell
proliferation, survival and migration [28].
In such view, present study demonstrated that therapeutic
NLGP treatment subcutaneously once weekly for 4 weeks in total
restricted melanoma growth and maintained 35% mice tumor free
on day 60 post treatment, in comparison to 5% mice in PBS treated
controls. Again, tumor growth rate of mice with progressed dis-
eases was signiﬁcantly less after NLGP treatment than similar mice
with PBS injections. This observation is in parallel to our earlier re-
port on sarcoma growth restriction by NLGP in Swiss mice [29]. As
NLGP is neither a killer of cancer cells nor normal cells [14], the
hypothesis is drawn on NLGP mediated immunomodulation. To
conﬁrm this hypothesis, we have sequentially analyzed different
cellular and soluble mediators in tumor immune compartments
from mice having PBS or NLGP treatment.
First attention was given on anti-tumor cytotoxic CD8+T-cells
[21]. Examination of such T cells from either PBS-TME or NLGP-
TME revealed reversal of subdued T-cell activity due to NLGP treat-
ment. In initial set of experiments, upregulation of CD8+T-cells
within NLGP-TME was observed and these cells have higher
expression of activation marker CD69, along with cytotoxic mole-
cules, perforin-granzyme B. In second set, normal T-cells were ex-
posed to PBS-TME and NLGP-TME and NLGP-TME exposed T-cells
function optimally, as examined by their proliferation, IFNc secre-
tion and tumor cell cytotoxicity. Furthermore, NLGP protects
CD8+T-cells from AICD. Thus, predominant effector cells can func-
tion optimally in NLGP inﬂuenced TME. In addition, immuno-
suppressive mechanisms operating in cancer patients signiﬁcantly
contribute to tumor progression and attenuate the efﬁcacy of
immunotherapies [30–32]. To elucidate the role of NLGP, we have
examined the suppressor cells, MDSCs and Tregs and their func-
tionally relevant molecules. Signiﬁcant downregulation of MDSCs
without any change in the level of Tregs was noted within TME.
However, transcription factor required for Treg functionality, i.e.,
Foxp3, is decreased in NLGP-TME. MDSC derived cytokines, like,
TGFb, IL-10, were downregulated that may offer optimum environ-
ment for anti-tumor T-cell functions.Effector and regulatory cells secrete various cytokines and che-
mokines depending on host tumor load. To ﬁnd out these changes,
tumors were harvested in day dependent manner from NLGP and
PBS treated mice to look for Type1 and non-Type1 cytokine levels
within TME. TME is generally non-type 1/regulatory cytokine dom-
inated with greater content of IL-10, TGFb and low IFNc, IL-12 lev-
els. We found that tumors of NLGP treated mice exhibited
signiﬁcant upregulated level of type1 cytokines (IL-2, IL-12 and
IFNc) (Fig. 3) in day dependent manner and reduced status of
IL-6, IL-10 and TGFb (type2 cytokines) (Fig. 3) within TME. This
anti-tumor cytokine microenvironment helps in tumor eradication
by several mechanisms. Although, these are yet to be identiﬁed,
here, we have detected downregulation of phospho STAT3 in cells
from NLGP-TME. STAT3 promotes the production of immunosup-
pressive factors (IL-6, IL-10 etc.) that phosphorylates STAT3 in di-
verse immune-cell subsets, altering gene-expression programs
and, thereby, restraining anti-tumor immune responses leading
to tumor-induced immunosuppression [33]. Simultaneously it is
well documented that elevated levels of signaling components pro-
mote STAT3 phosphorylation in many tumor types and associated
with a poor prognosis [34–36].
Chemokine-mediated T-cell migration is essential for optimal
anti-tumor immune responses [22]. Resembling the cytokine net-
work, chemokine milieu is also dysregulated within TME, thus,
hampers homing of effector CD8+T-cells in tumors. To ascertain
chemokine receptor-ligand proﬁle, we have analyzed cxcr3 and
ccr5, and their corresponding ligands. It was found that ligands
for ccr5 like ccl3, ccl4, ccl5 and ccl8 were increased within NLGP-
TME. Same trends of up-regulation were observed in case of cxcl9,
cxcl10, ligands for cxcr3. We also observed a marked down-
regulation of cxcr4 and cxcl12 in NLGP treated tumors. In vitro
studies suggested earlier that NLGP is efﬁcient to correct cxcr3
and ccr5 dependent migration of lymphocytes and monocytes in
HNSCC [15]. Obtained results suggest that chemokine gradients
are normalized within NLGP-TME.
In conclusion, our data suggest that NLGP is efﬁcient to dimin-
ish tumor growth by activating subdued T-cell functions within
TME in co-operation with normalization of hyperactive suppressor
cellular functions andmaintaining optimum type-1/regulatory bal-
ance. NLGP may normalize pathological angiogenesis during
regression of melanoma tumors as indicated by lowering of VEGF,
VEGFR2 and HIF1a. Detail study in this ﬁeld is awaiting.Conﬂict of Interest
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